Key terms
About ANGO
AngioDynamics, Inc. operates as a medical device company, which engages in the development, manufacturing and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It operates through the Med Tech and Med Device segments. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ANGO news
Apr 05
12:25pm ET
Buy Rating Affirmed for AngioDynamics Amid Strong Sales and Strategic Growth Opportunities
Apr 05
9:38am ET
Krispy Kreme upgraded, Altice USA downgraded: Wall Street’s top analyst calls
Apr 05
7:51am ET
AngioDynamics upgraded to Outperform from Perform at Oppenheimer
Apr 05
7:15am ET
AngioDynamics upgraded to Outperform from Perform at Oppenheimer
Apr 05
6:56am ET
Buy Rating Reaffirmed for AngioDynamics Amidst Strategic Growth and Med-Tech Sector Potential
Apr 04
7:42am ET
AngioDynamics Unveils Financial Outlook and Growth Plans
Apr 04
7:06am ET
AngioDynamics reports Q3 adjusted EPS (16c), consensus (13c)
Apr 04
7:05am ET
Options Volatility and Implied Earnings Moves Today, April 04, 2024
Apr 04
6:50am ET
AngioDynamics’ AlphaVac F18 system receives 510(k) clearance for PE
Apr 01
5:21pm ET
AngioDynamics settles litigation with Becton Dickinson
Apr 01
7:00am ET
Options Volatility and Implied Earnings Moves This Week, April 01 – April 05, 2024
Feb 22
7:46am ET
AngioDynamics price target raised to $18 from $17 at Canaccord
Feb 16
6:20am ET
Analysts’ Top Healthcare Picks: AngioDynamics (ANGO), Corcept Therapeutics (CORT)
Feb 16
6:13am ET
AngioDynamics price target lowered to $14 from $18 at H.C. Wainwright
Feb 15
4:14pm ET
AngioDynamics sells PICC, Midline product portfolios for up to $45M in cash
Feb 13
4:26pm ET
AngioDynamics Announces Key Leadership and Board Changes
Jan 23
8:10am ET
FDA clears AngioDynamics Auryon XL Catheter to treat Peripheral Arterial Disease
Jan 23
3:07am ET
AngioDynamics’ Long-Time Director Meteny Retires
Jan 08
7:55am ET
Oppenheimer Keeps Their Hold Rating on AngioDynamics (ANGO)
Jan 08
7:25am ET
AngioDynamics price target lowered to $17 from $19 at Canaccord
Jan 08
6:26am ET
Buy Rating Maintained for AngioDynamics Amidst Strategic Restructuring and New Product Launches
Jan 08
6:24am ET
AngioDynamics price target lowered to $18 from $20 at H.C. Wainwright
No recent press releases are available for ANGO
ANGO Financials
Key terms
Ad Feedback
ANGO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ANGO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range